These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34668876)

  • 1. Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms.
    Lindenmayer JP; Burke E; Tsuboyama G; Chahal Y; Grewal HK
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):109-111. PubMed ID: 34668876
    [No Abstract]   [Full Text] [Related]  

  • 2. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    Khurram SK; Ames M; Muniz J
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):220-221. PubMed ID: 33587391
    [No Abstract]   [Full Text] [Related]  

  • 3. Valbenazine for the treatment of tardive dyskinesia.
    Müller T
    Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
    Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
    J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T
    Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valbenazine-induced parkinsonism.
    Akbar U; Kim DS; Friedman JH
    Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
    Correll CU; Citrome L; Singer C; Lindenmayer JP; Zinger C; Liang G; Dunayevich E; Marder SR
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):353-361. PubMed ID: 38767901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.